Liraglutide has been approved for multiple indications since its initial launch in 2010: 2010: Victoza approved for adults with type 2 diabetes 2014: Brand name Saxenda approved for obesity in adults 2017: Victoza approved for reducing the risk of major adverse cardiovascular (CV) events, heart attack, stroke, and CV death in adults with type 2 diabetes and established CV disease 2019: Victoza approved for pediatric patients aged ten and over with type 2 diabetes 2020: Saxenda approved for obesity in adolescents aged 12-17 Population According to the CDC, approximately 38 million adults in the United States have diabetes (90-95% is type 2 diabetes)
Since T3 directly stimulates hair follicle keratinocyte proliferation, even subtle declines can slow hair growth or push follicles into premature catagen and telogen
New in JCEM: using our ExoSORT platform with Dr
Provide education on lifestyle factors that can contribute to hypoglycemia, such as meal timing, physical activity, and medication adherence
Oversight in 2025 shows that the agency is watching the GLP-1 space (diabetes, obesity, weight loss drugs) particularly closely, compounded versions or unverified imports will face tough regulatory headwinds
Maybe it also said nursing and I missed it
